Findings

What do systematic reviews say?

2,293 questions · 2,395 findings · 172 reviews · Gut

Sort:Best matchNewestHighest certainty Download CSV

No studies found 420 · 17.5%GRADE not reported 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Infliximab vs placebo

IBDQ at week 6 · people with active UC

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 529 participants
High

Infliximab vs placebo

EQ‐5D at week 6 · people with active UC

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

Infliximab vs placebo

Health‐related quality of life · people with active UC

Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
RR 1.51 [1.23, 1.85]
1 study · 728 participants
Moderate

Infliximab vs placebo

Improved SF‐36 MCS at week 8 · people with active UC

Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
RR 1.44 [1.16, 1.79]
1 study · 728 participants
Moderate

Adalimumab vs placebo

Improved IBDQ at week 8 · people with active UC

Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
RR 1.23 [1.06, 1.43]
2 studies · 767 participants
Moderate

Adalimumab vs placebo

Improved IBDQ at week 52 · people with active UC

Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
RR 1.73 [1.28, 2.34]
2 studies · 767 participants
Moderate

Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant

Postoperative pancreatic fistula (ISGPF definition) · people undergoing distal pancreatectomy

Stapler showed no clear difference in postoperative Pancreatic Fistula compared with scalpel resection followed by hand‐sewn closure of the pancreatic… (moderate certainty).

1 finding from 1 review

Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy 2015 · Cochrane Headline outcomes only
RR 0.9 [0.55, 1.45]
2 studies · 381 participants
Moderate

Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant

All‐cause mortality · people undergoing distal pancreatectomy

Stapler showed no clear difference in mortality compared with scalpel resection followed by hand‐sewn closure of the pancreatic… (moderate certainty).

1 finding from 1 review

Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy 2015 · Cochrane Headline outcomes only
RR 0.49 [0.05, 5.4]
2 studies · 381 participants
Moderate

Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant

Operating time · people undergoing distal pancreatectomy

Stapler showed no clear difference in operation Time compared with scalpel resection followed by hand‐sewn closure of the pancreatic… (moderate certainty).

1 finding from 1 review

Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 381 participants
Moderate

Drain vs No drain

30‐day mortality Death during the · gastric cancer

It is very uncertain whether drain changes 30‐day mortality Death during the compared with no drain (very low certainty).

1 finding from 1 review

Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
RR 1.73 [0.38, 7.84]
4 studies · 438 participants
Very low

Drain vs No drain

Post‐operative complications · gastric cancer

1 finding from 1 review

Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 4 participants
Low

Drain vs No drain

Reoperation · gastric cancer

It is very uncertain whether drain changes re‐operations Re‐operations during the compared with no drain (very low certainty).

1 finding from 1 review

Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
RR 2.49 [0.71, 8.74]
2 studies · 230 participants
Very low

Drain vs No drain

Operation time The time from the start to the end of operation. Scale from: 0 to 100. · gastric cancer

1 finding from 1 review

Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 378 participants
Low

Drain vs No drain

Length of postoperative hospital stay · gastric cancer

1 finding from 1 review

Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 438 participants
Low

Immunonutrition vs control

All‐cause mortality · patients with acute pancreatitis

Immunonutrition may leads to lower all‐cause mortality compared with control (low certainty).

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
RR 0.49 [0.29, 0.8]
6 studies · 520 participants
Low

Immunonutrition with probiotics and fibres vs control

All‐cause mortality · patients with acute pancreatitis

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

Immunonutrition with probiotics and fibres vs control

Systemic inflammatory response syndrome ‐ not reported · patients with acute pancreatitis

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Immunonutrition with probiotics and fibres vs control

Organ failure ‐ not reported · patients with acute pancreatitis

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Immunonutrition with probiotics and fibres vs control

Adverse events ‐ not reported · patients with acute pancreatitis

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Semi‐elemental enteral nutrition vs control

All‐cause mortality · patients with acute pancreatitis

1 finding from 1 review

Enteral nutrition formulations for acute pancreatitis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Very low